Document is current

Article History

Received: 17 February 2022

Accepted: 20 April 2022

First Online: 18 May 2022

Disclosures

: Susan M. Swetter, Clara Curiel-Lewandrowski, Stephen W. Dusza, Amy L. Tin, Andrew J. Vickers, and Michael A. Marchetti report no conflicts of interest. Edmund K. Bartlett reports receiving institutional research funding from SkylineDx and an honorarium from Excite International unrelated to the content of this work. Jeffrey E. Gershenwald has been on an advisory board and/or consultant for Merck, Bristol Myers Squibb, and Regeneron in the past 24 months, unrelated to the content of this work. Douglas Grossman is an investigator for Dermtech, Inc. and Orlucent, Inc., and serves on the advisory board for Orlucent, Inc., all unrelated to the content of this work. Sancy A. Leachman receives research support from Orlucent, Inc., DermDetect, and Myriad Genetics Laboratory, and serves on an advisory board for Orlucent, Inc., VeriSkin, Inc., and Merck. John M. Kirkwood has been on an advisory board and/or consultant for Amgen Inc., Ankyra Therapeutics, Axio Research, Becker Pharmaceutical, Bristol Myers Squibb, Checkmate Pharmaceuticals, DermTech, Elsevier, Fenix Group International, Harbour Biomed, Immunocore LLC, Intellisphere LLC, Iovance Biotherapeutics, IQVIA, Istari Oncology, Merck, Millennium Pharmaceuticals, Natera Inc., Novartis Pharmaceuticals, OncoCyte Corp., OncoSec Medical Inc., Pfizer, Replimune, Scopus BioPharma, and SR One Capital Management, and receives institutional research support from Amgen, Bristol Myers Squibb, Castle Biosciences, Checkmate Pharmaceuticals, Immvira Pharma Co., Immunocore LLC, Iovance Biotherapeutics, Lion Biotechnologies, Merck, Novartis Pharmaceuticals, and Schering-Plough, all unrelated to the content of this work.